HOX11L2 expression, mostly resulting from the chromosomal cryptic translocation t(5;14)(q35;q32), is observed in more than 20% of childhood T-cell acute lymphoblastic leukemia (T-ALL) and in about 13% of adult T-ALL. 1, 2 The prognostic significance of the genetic abnormality in patients with this subtype of ALL is still controversial, claimed as unfavorable for some groups 3, 4 or regarded as neutral for others. 5, 6 Recently, episomal amplification encompassing the ABL1 gene has been found in 2.3 and 4.3% of childhood and adult T-ALL. 7 The incidence of ABL1 amplification rose to 5.8% of T-ALL by Graux et al, 8 who showed that a new fusion gene, NUP214-ABL1, was included in the episomal amplicon. Moreover, the latter authors showed that the NUP214-ABL1 fusion was mainly present in T-ALL expressing HOX11 or HOX11L2. We hypothesized that the expression of the fusion gene might account for the discrepancies observed in the evolution of individual HOX11L2-positive patients with T-ALL. We report the finding of fluorescence in situ hybridization (FISH) and real-time PCR in a child with T-ALL with a peculiar form of amplification and rapidly fatal evolution.
Case report
GD, a 9-year-old boy was admitted to the hematological unit of the Armand Trousseau hospital (Paris) with a suspicion of leukemia because of fever, erythematous angina, enlarged cervical lymph nodes and hyperleukocytosis. Clinical and radiological examination displayed mediastinal enlargement, hepatosplenomegaly and voluminous mesenteric lymph nodes. Hematologic data confirmed the diagnosis of acute leukemia: in peripheral blood, 302 Â 10 9 /l leukocytes with 93% lymphoblasts, 116 Â 10 9 /l platelets and hemoglobin 117 g/l. Immunophenotyping revealed an immature T-cell leukemia scoring positive for c-CD3, CD2, CD4, CD5, CD7 and CD8 antigens. All the myeloid antigens tested (CD13, CD14, CD15, CD33, CD117, CD35 and c-MPO) were negative, with the exception of CD33. The child immediately received induction therapy including prednisolone prephase, vincristine 1. 
FISH studies
Two series of FISH studies were performed according to usual techniques. 9 The first allowed the detection of a t(5;14) translocation with dual-color FISH with whole chromosome 14 painting probe and YAC 885A6, as described previously. 1 The chromosomal breakpoints were more precisely located with BAC probes, on chromosome 5 between BACs 45L16 remaining to chromosome 5 and 546B8 translocated to 14q32 (without split), and on chromosome 14 to BAC 2576L4 giving split signals on normal chromosome 14, der (14) and der(5). In the second step, amplification of ABL1 was investigated with the commercial LSI BCR-ABL1 ES dual probe covering 300 kb of ABL1 from intron 5 toward telomere (Abbott, Rungis). Surprisingly, a strong signal was present on the long arm of chromosome 2 in addition to the normal signals on both 9q34 copies. No extrachromosomal hybridization signal could be observed. It was concluded that amplification of ABL1 sequences were located to 2q23-24. Hybridization with whole chromosome 9 painting (WCP) probe also showed a signal on 2q, consistently less strong that the signal obtained with ABL probes alone. The difference of the two signals was evidenced by dual-color FISH with ABL and chromosome 9 WCP probe showing that the signals generated by the ABL probe were larger than those of the WCP probe. To ascertain the involvement of NUP214, dual-color FISH studies were performed with BACs RP11 235J21 (ABL1) and RP11-235F20 and RP11-106L9 (NUP214). Colocalization of ABL1 and NUP214 probes to both chromosomes 9 as well as to chromosome 2q confirmed the amplification of DNA sequences of the two genes (Figure 1 ).
Molecular studies
Molecular studies included TLX3 expression analysis. The leukemia cells expressed high levels of the TLX3 gene in keeping with the presence of t(5;14)(q35;q14). At the time of the observation, the episomal rearrangement NUP214-ABL1 was not yet identified. Retrospective search for the gene fusion was performed as in Graux et al. 8 We could amplify a specific PCR fragment of 0.7 kb with primers NUP29F-ABL1R3 and a shorter fragment of 0.45 kb with primers NUP31F-ABL1R0. This result suggests that the breakpoint was located downstream of exon 31 in the NUP214 gene. Real-time quantitative RT-PCR (RQ-PCR) was also performed to quantify the expression of ABL1, described as abnormally high in patients with the NUP214-ABL1 gene fusion. Primers and probe for ABL1 were as in Beillard et al 10 and detected both wild-type and rearranged ABL1. Expression of TBP (Transcription Factor IID) gene, a control gene steadily expressed in normal and leukemic cells, was used to normalize the ABL1 expression values. Those for TBP were as in Bièche et al. 11 First, we determined ABL1 expression values in a panel of 50 T-ALLs, all tested negative for NUP214-ABL1 rearrangement, and in a pool of normal fetal thymus (Stratagene, Europe, Amsterdam). The expression values of ABL1 gene were moderately heterogeneous among T-ALLs, varying from 0.45-to 2.5-fold expression over TBP (mean ¼ 1.2). Higher expression, 2.7-fold value, was observed in the pool of normal fetal thymus. Among the nine TLX3-and two TLX1-positive leukemias included in the T-ALL panel, the quantified ABL1 values varied in the same range, from 0.37 to 2.26 (mean ¼ 1.39), thus ruling out a possible role of TLX3 or TLX1 gene products in the transcriptional regulation of the normal ABL1 gene or a specific association between high expression levels of both genes.
As expected, ABL1 was significantly overexpressed in the recorded case (8.1-fold increase over TBP expression). This value was also significantly higher than that estimated in three other NUP-ABL1-positive T-ALLs (data not shown).
Discussion
Discrepancies about the prognostic value of t(5;14)(q35;q32)/ HOX11L2-positive ALL, on the one hand, and the report of amplification of a new fusion NUP214-ABL1 gene, on the other hand, prompted us to search for such amplification in patients with t(5;14). As amplification of NUP214-ABL may be related with a poor evolution of the disease, it was logical to examine cells of patients with unfavorable outcome. Study of leukemic cells of a child with t(5;15)/HOX11L2-positive T-ALL revealed the presence of amplified NUP214 and ABL sequences located to the long arm of one chromosome 2. This morphologic pattern of amplification of NUP214-ABL1 was not reported previously. 8 In the reported observations, the amplicons resulted from the formation of episomes, not seen in the present case. It is generally admitted that the first step of genomic amplification of genomic DNA results from episome formation. 12, 13 In latter steps, the episomes may be included within double minute (dmin) chromosomes or homogeneously staining or abnormally staining regions (HSR or ABR).
14 Two mechanisms for the formation of amplicons have been proposed, conservative in which the original DNA sequence remains at its normal location onto the chromosome, and nonconservative in which the original sequence is extracted from its normal chromosomal location. 15 With the first mechanism, FISH with appropriate probes shows hybridization to the normal loci of sequences from which the amplicons derive, and with the second mechanism, only one locus is marked with the probe. Whereas the second mechanism is involved in the materials studied by Graux et al, 8 the conservative mechanism is implied in the case here reported. Moreover, the localization of the amplified NUP214-ABL1 sequences on chromosome 2q21 might be favored by the peculiar structure of band 2q21 where an alphoid DNA sequence, conserved in human and great ape chromosomes, is located. 16 We examined two other children with t(5;14)T-ALL, one with amplification of NUP214-ABL1 in its episomal form who died from his leukemia two and half years after the diagnosis, and the second without genomic amplification who remains in continuous complete remission 18 months after the diagnosis. Whether the mechanism of amplification has any impact to its biological consequences is still to be determined.
Whatever the case, the detection of the amplified DNA NUP214-ABL1 fusion may be important for the treatment of the patients, since it appears that imatinib mesylate (Gleevec) is potentially efficient. 8 We therefore conclude that search for the NUP214-ABL1 rearrangement, which is cryptic in its episomal form, must now be systematically included in the exploration of patients with t(5;14)/HOX11L2-positive ALLs. Such studies should also be carried out in HOX11-positive T-ALL patients since this leukemia subtype can also be associated with NUP214-ABL1 amplification. FISH to metaphase chromosomes of the patient with probes BAC RP11-235F20 and RP11-10L9 (NUP214) (green) and RP11 235J21 (ABL) (red). Signals green-red on both chromosomes 9 and amplified sequences on 2q. Also note the different sizes of amplified and normal signals in interphase nuclei.
